Engineered Probiotics for Treatment and Immunity Against Viruses
Summary
The USPTO granted Patent US12605413B2 to the University of Cincinnati covering an engineered probiotic bacterium comprising heterologous nucleic acid encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917 with the nanobody appearing on the bacterial surface. The patent contains 9 claims and was filed on April 19, 2021.
What changed
The USPTO issued Patent US12605413B2 to the University of Cincinnati for an engineered probiotic bacterium designed to express anti-spike glycoprotein nanobodies of coronaviruses. The patent covers recombinant E. coli Nissle 1917 bacteria displaying the nanobody on their surface as a therapeutic or immunity-inducing agent. Nine claims were allowed in the patent.
Biotechnology and pharmaceutical entities developing probiotic-based therapeutics, coronavirus treatments, or nanobody platforms should review this patent for potential freedom-to-operate implications. The patent's broad claim scope covering surface-displayed anti-spike nanobodies on E. coli Nissle 1917 may affect competing research programs in this space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Engineered probiotics for treatment and immunity against viruses
Grant US12605413B2 Kind: B2 Apr 21, 2026
Assignee
University of Cincinnati
Inventors
Nalinikanth Kotagiri, Nitin S. Kamble
Abstract
The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.
CPC Classifications
C07K 2317/569 C07K 16/1003 A61K 2035/115 A61K 35/741 A61P 31/14
Filing Date
2021-04-19
Application No.
17919424
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.